{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:20Z","timestamp":1759336520152,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["MOP-130363"],"award-info":[{"award-number":["MOP-130363"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canada-Brazil bilateral","award":["DFATD-CAPES-88887","137283\/2017\u201300"],"award-info":[{"award-number":["DFATD-CAPES-88887","137283\/2017\u201300"]}]},{"DOI":"10.13039\/100014131","name":"Research Institute of the McGill University Health Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejmech.2020.112185","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:37:55Z","timestamp":1582717075000},"page":"112185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules"],"prefix":"10.1016","volume":"192","author":[{"given":"Julie","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela N.F.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela N.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem M.","family":"Titi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand J.","family":"Jean-Claude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112185_bib1","doi-asserted-by":"crossref","first-page":"4227s","DOI":"10.1158\/1078-0432.CCR-040007","article-title":"The biology of epidermal growth factor receptor in lung cancer","volume":"10","author":"Scagliotti","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112185_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.1993.306","article-title":"The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival","volume":"68","author":"Veale","year":"1993","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112185_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bjc.1998.106","article-title":"Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas","volume":"77","author":"Volm","year":"1998","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112185_bib4","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.ejmech.2020.112185_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of non\u2013small-cell lung cancer with erlotinib or gefitinib","volume":"364","author":"Cataldo","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112185_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status","volume":"8","author":"Zhong","year":"2015","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2020.112185_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2050-7771-1-2","article-title":"EGFR inhibition in non-small cell lung cancer: current evidence and future directions","volume":"1","author":"Chi","year":"2013","journal-title":"Biomarker Research"},{"key":"10.1016\/j.ejmech.2020.112185_bib8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3747\/co.25.3796","article-title":"Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials","volume":"25","author":"O\u2019Kane","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2020.112185_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccell.2015.05.012","article-title":"The next wave of EGFR tyrosine kinase inhibitors enter the clinic","volume":"27","author":"Politi","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2020.112185_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","article-title":"Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2020.112185_bib11","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-18-3829","article-title":"On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation","volume":"25","author":"Brown","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112185_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.critrevonc.2018.01.013","article-title":"Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives","volume":"123","author":"Tomasello","year":"2018","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.ejmech.2020.112185_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2019.05.044","article-title":"Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives","volume":"459","author":"Zhang","year":"2019","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2020.112185_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2407-4-83","article-title":"The in\u00a0vitro effect of gefitinib (\u2019Iressa\u2019) alone and in combination with cytotoxic chemotherapy on human solid tumours","volume":"4","author":"Knight","year":"2004","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejmech.2020.112185_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cellsig.2010.11.014","article-title":"The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle","volume":"23","author":"Banerjee","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2020.112185_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1535-7163.MCT-09-0673","article-title":"Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species","volume":"9","author":"Todorova","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112185_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acsmedchemlett.6b00358","article-title":"Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: BGCNU","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112185_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4155\/fmc-2016-0229","article-title":"The potential of combi-molecules with DNA-damaging function as anticancer agents","volume":"9","author":"Sun","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.109.160085","article-title":"The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24","volume":"334","author":"Banerjee","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112185_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2015.01.026","article-title":"ZRBA1, a mixed EGFR\/DNA targeting molecule, potentiates radiation response through delayed DNA damage repair process in a triple negative breast cancer model","volume":"92","author":"Heravi","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2020.112185_bib21","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1021\/jm070144p","article-title":"Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid Tumors: discovery of an unusual Structure\u2212Activity relationship","volume":"50","author":"Rachid","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bmcl.2004.12.015","article-title":"Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status, Bioorg","volume":"15","author":"Rachid","year":"2005","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112185_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.20383","article-title":"Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA","volume":"112","author":"Brahimi","year":"2004","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112185_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/jpet.102.039099","article-title":"Inhibition of epidermal growth factor receptor-mediated signaling by \u201ccombi-triazene\u201d BJ2000, a new probe for combi-targeting postulates","volume":"303","author":"Brahimi","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112185_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117215","article-title":"Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting","volume":"10","author":"Rao","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112185_bib26","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1158\/1078-0432.CCR-19-0955","article-title":"Mechanisms and antitumor activity of a binary EGFR\/DNA\u2013Targeting strategy overcomes resistance of glioblastoma stem cells to temozolomide","volume":"25","author":"Sharifi","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112185_bib27","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.bmc.2011.01.055","article-title":"Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates","volume":"19","author":"Marvania","year":"2011","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2013.06.055","article-title":"Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer","volume":"67","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejmech.2016.12.055","article-title":"Design, synthesis and biological evaluation of quinazoline\u2013phosphoramidate mustard conjugates as anticancer drugs","volume":"127","author":"Lin","year":"2017","journal-title":"Eur. J. Med. Chem."},{"year":"2004","series-title":"Novel Combi-Molecules Having EGFR and DNA Targeting Properties, in, canada","author":"Jean-Claude","key":"10.1016\/j.ejmech.2020.112185_bib30"},{"key":"10.1016\/j.ejmech.2020.112185_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1747-0285.2008.00638.x","article-title":"Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase","volume":"71","author":"Larroque","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112185_bib32","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/jm030142e","article-title":"The combi-targeting Concept: chemical dissection of the dual targeting properties of a series of \u201ccombi-triazenes\u201d","volume":"46","author":"Rachid","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib33","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2147\/OTT.S73731","article-title":"Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line","volume":"8","author":"Yan","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2020.112185_bib34","doi-asserted-by":"crossref","first-page":"79503","DOI":"10.18632\/oncotarget.12806","article-title":"KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models","volume":"7","author":"Kenessey","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112185_bib35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejmech.2008.01.009","article-title":"2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents","volume":"44","author":"Zhang","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib36","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/jm400463q","article-title":"Novel hybrids of (Phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer","volume":"56","author":"Han","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112185_bib37","series-title":"Medicinal Chemistry of Anticancer Drugs","first-page":"139","article-title":"Chapter 5 - DNA alkylating agents","author":"Avenda\u00f1o","year":"2008"},{"key":"10.1016\/j.ejmech.2020.112185_bib38","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1021\/tx990089q","article-title":"DNA adducts of 9-anilinoacridine Mustards: characterization by NMR","volume":"12","author":"Fan","year":"1999","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2020.112185_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0009-2797(85)80094-6","article-title":"The influence of N7 substituents on the stability of N7-alkylated guanosines","volume":"53","author":"M\u00fcller","year":"1985","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2020.112185_bib40","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1078-0432.CCR-07-1606","article-title":"Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity","volume":"14","author":"Tanaka","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112185_bib41","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1073\/pnas.95.20.12022","article-title":"Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor","volume":"95","author":"Fry","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:07:33Z","timestamp":1759327653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420301525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"alternative-id":["S0223523420301525"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112185","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112185"}}